Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Current Liabilities (2016 - 2025)

Lexaria Bioscience's Total Current Liabilities history spans 10 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 389.1% year-over-year to $1.5 million; the TTM value through Nov 2025 reached $1.5 million, up 389.1%, while the annual FY2025 figure was $1.5 million, 35.84% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $1.5 million at Lexaria Bioscience, down from $1.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.8 million in Q1 2025 and bottomed at $81717.0 in Q1 2024.
  • The 5-year median for Total Current Liabilities is $252717.0 (2021), against an average of $571316.2.
  • The largest annual shift saw Total Current Liabilities tumbled 85.22% in 2024 before it soared 2130.16% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $237699.0 in 2021, then increased by 18.44% to $281520.0 in 2022, then crashed by 55.77% to $124523.0 in 2023, then surged by 139.15% to $297798.0 in 2024, then skyrocketed by 389.1% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Total Current Liabilities are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).